Tardive dyskinesia is a common side effect caused by antipsychotic use. It is a neurological disorder characterized by involuntary, repetitive movements, often involving the face, mouth, tongue, and ...

Tardive dyskinesia (TD) is a movement disorder. It’s a side effect of taking neuroleptic drugs. Treatment is focused on stopping the recurrence or persistence of symptoms. Tardive dyskinesia (TD) is a ...

Patients on antipsychotics need to be regularly monitored for signs of tardive dyskinesia, a medication-induced movement disorder diagnosed when the involuntary movements persist for at least a month ...

The gold standard is the Abnormal Involuntary Movement Scale, or the AIMS, although generally we kind of want to avoid premature TD labels, and we want to ensure that there's a causal link, in this ...

Tracking your tardive dyskinesia symptoms provides insight into what’s going on. Tardive dyskinesia (TD) is a movement disorder that causes certain uncontrollable movements in different parts of the ...

Differentiating tardive dyskinesia from other movement disorders can be challenging. "One major criterion is the history of exposure to neuroleptic medications," said Jeff Bronstein, MD, PhD, of the ...

Antipsychotic treatment can cause involuntary movements such as lip smacking, tongue protrusions and excessive eye blinking. These movements typically occur after more than 3 months of treatment and ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription ...

A 36-year-old man with a diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), was referred to a psychiatry clinic for severe, ...

Some studies suggest vitamin E may help ease symptoms of tardive dyskinesia — but how strong is the evidence, and what does it really tell us? Note: The U.S. Food and Drug Administration (FDA) does ...

This story also appeared on Everyday Heath's network site BP Hope. The U.S. Food and Drug Administration (FDA) has approved a new sprinkle formulation of valbenazine (Ingrezza) for individuals with ...